{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-100078","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.886033+00:00","generated_at":"2026-06-29T22:27:17.097016+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Protagonist Q2 net loss $30.8M; rusfertide gets FDA Breakthrough Therapy; Phase 3 on track","bullets":["Net loss $30.8M ($0.69/share) vs $19.4M ($0.59) in Q2 2020; cash $380.4M expected to fund through 2024.","Rusfertide granted FDA Breakthrough Therapy for polycythemia vera; Phase 3 start expected early 2022.","Janssen collaboration amended: Janssen leads worldwide development; Protagonist eligible for ~$900M milestones plus $80M received.","Completed public offering of 3.5M shares at $37.75, raising ~$132.2M gross proceeds.","PN-943 Phase 2 data for ulcerative colitis anticipated in Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-100078","json":"https://secwatch.observer/filing/0001104659-21-100078.json","markdown":"https://secwatch.observer/filing/0001104659-21-100078.md","text":"https://secwatch.observer/filing/0001104659-21-100078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465921100078/0001104659-21-100078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465921100078/tm2124049d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:27:17.097016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}